[Photo provided by Samsung Biologics Co.]
South Korea’s Samsung Biologics bagged an end-to-end contract development and manufacturing organization (CDMO) deal from U.S. drug developer Enzolytics Inc. to manufacture and supply the client’s HIV and Covid-19 treatments, according to the Korean CDMO giant said on Thursday.
Financial terms were not disclosed.
Under the contract, Samsung Biologics will provide CDMO services for Enzolytics’ HIV and Covid 19 treatments ranging from cell line development, clinical drug substance, and drug product manufacturing services to support monoclonal antibodies.
The Korean company said that both parties will continue to discuss CDMO services for “other monoclonal antibodies being developed by Enzolytics.”
Enzolytics develops antibody treatments that can respond to variant viruses by targeting conserved immutable sites within the virus based on artificial intelligence platform in injection form.
Samsung Biologics plans to provide support for Enzolytics’ cell line development through its contract development organization (CDO) research and development (R&D) center in San Francisco in U.S. Candidate materials production for clinical trials will be carried out at its facility in Songdo, Incheon, Korea.
“Partnering with Enzolytics reinforces the value of our fully integrated, end-to-end business model, which is designed to meet the unique needs and goals of our biotech clients,” said John Rim, chief executive of Samsung Biologics. “We look forward to providing comprehensive services and professional support for the manufacturing of this important class of monoclonal antibody therapeutics for the treatment of HIV and SARS-CoV-2, helping to accelerate the process of drug development to IND filing and bring these life-saving products to patients.”
“The collaboration with Samsung Biologics is a significant milestone for Enzolytics’ artificial intelligence enabled monoclonal antibody platform,” said Guarav Chandra, chief operating officer research and development at Enzolytics. “We chose to partner with Samsung Biologics because of Samsung Biologics’ extensive experience and expertise in developing, producing, and manufacturing monoclonal antibodies for infectious diseases and oncology.”
Shares of Samsung Biologics finished Friday up 1.84 percent at 830,000 won ($694.27) in Seoul.
By Park Yoon-gyun and Lee Eun-joo
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]